The remarkable technologic and methodologic advances spurred on by the Human Genome Project are being applied throughout the life sciences. In the field of toxicology, high-resolution assays now make it possible to discover virtually all the differences in gene expression brought on by exposure to a particular xenobiotic. There are 2 principal approaches used to build a catalog of changes in gene expression: hybridization microarrays and gel-based methods, such as differential display and AFLP&trade;-based mRNA fingerprinting. The power of such approaches is exemplified by the identification of more than 300 genes that differ in expression level by at least 2-fold in response to the nongenotoxic rodent liver carcinogen phenobarbital.
INTRODUCTION
Genomics encompasses a variety of related topics, including pharmacogenomics and bioinformatics, with each of these topics being worthy of their own separate review. In this brief overview of genomics, however, we focus on high-throughput, high-resolution molecular biology methods for the determination of virtually all toxicantinduced changes in gene expression. The ultimate goal in creating a catalog of toxicant-induced gene expression changes is 2-fold: (a) to better predict animal toxicity to reduce costs, timelines, and animal use by enhancing the probability that product candidates chosen for further development will pass regulatory testing requirements and (b) to better predict human toxicity, resulting in fewer compounds that fail in clinical trials and better safeguards for human health.
The basis for these types of investigations is the expectation that toxicologic endpoints (e.g., tumor formation) are (Table I) . This is a reflection of the ability to reduce the complexity of the AFLP@ gel profile by using primers with additional selective nucleotides; in this way, fragments can be isolated free from contaminating fragments. The 10 TDF sequences were compared against sequences in GenBank using the BLASTN algorithm, system: only 3 of the 10 TDF sequences matched rat sequences in the public databases, i.e., 7 of the 10 TDF sequences were undescribed for the rat, with 2 of them undescribed for any species. A closed system, such as a rat microarray based on GenBank sequences, would have missed 7 of the 10 sequences detected by this method. A complete profile of differences that are >2-fold in either up-or down-regulation has now been completed, with >300 differences detected, isolated, and sequenced ( Fig.  2 shows examples of such up-and down-regulated TDFs). Categories include unknown novel genes, metabolism genes, and transcription factors, among many others. To facilitate the use of these markers in screening studies, the expression of a subset of these genes is being analyzed in samples treated with phenobarbital for 2 wk; these results will be reported elsewhere. 
